Abstract: Methods for (i) inhibiting the induction and formation of osteoclasts, (ii) inhibiting RANKL expression in osteoblasts, (ii) inhibiting the activation of osteoclasts and (iv) inhibiting a decrease in bone density by administering to a warm-blooded animal in need thereof a pharmacologically effective amount of a compound selected from the group consisting of olmesartan and olmesartan medoxomil, a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof.

Abstract: A method for treating a bone metabolic disease by administering to a human a pharmacologically effective amount of an angiotensin II receptor antagonist which is a compound of the following formula (I), a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof: wherein R1 represents a C1-C4 alkyl; R2 and R3 are the same or different and each represent hydrogen or a C1-C4 alkyl; R4 represents hydrogen or a C1-C4 alkyl; R5 represents hydrogen, a C1-C4 alkyl, a C2-C5 alkanoyloxymethyl, 1-(C2-C5 alkanoyloxy)ethyl, a C1-C4 alkoxycarbonyloxymethyl, 1-(C1-C4 alkoxycarbonyloxy)ethyl, a (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl, a (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methyl or a phthalidyl; and R6 represents a carboxy or a tetrazole-5-yl.

Abstract: A composition for delivering a biologically active agent to a specific site in the living body comprises microbubble-encapsulated albumin microspheres containing perfluorocarbon. The biologically active agent is preferably at least one agent selected from the group consisting of oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, oligonucleotide probes, nucleotide vectors, viral vectors, and plasmids. When the composition is used, the specific site is exposed to ultrasound so that the biologically active agent can be incorporated in the specific site.